TTY Biopharm Co Ltd (4105) — Capital Reinvestment Ratio

Latest as of December 2025: 0.04x

TTY Biopharm Co Ltd (4105) has a Capital Reinvestment Ratio of 0.04x as of December 2025, meaning it reinvests 0% of its operating cash flow (NT$778.89 Million) in capital expenditures (NT$34.72 Million). See TTY Biopharm Co Ltd balance sheet quality to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.04x
Capex / Operating Cash Flow

Operating Cash Flow

NT$778.89 Million
TWD

Capital Expenditures

NT$34.72 Million
TWD

Data as of

Dec 2025
Most recent filing

TTY Biopharm Co Ltd Capital Reinvestment Ratio (2017–2025)

This chart tracks TTY Biopharm Co Ltd's Capital Reinvestment Ratio across 9 annual periods. Check TTY Biopharm Co Ltd total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for TTY Biopharm Co Ltd (2017–2025)

Year-by-year Capital Reinvestment Ratio for TTY Biopharm Co Ltd from 2017 to 2025. For live market cap and broader valuation context, see market cap of TTY Biopharm Co Ltd.

Year Reinvestment Ratio Operating CF (TWD) Capital Expenditures YoY Change
2025 0.09x NT$1.76 Billion NT$150.83 Million ▼ -14.0%
2024 0.10x NT$1.35 Billion NT$134.29 Million ▲ +8.5%
2023 0.09x NT$1.09 Billion NT$99.58 Million ▼ -16.3%
2022 0.11x NT$1.24 Billion NT$135.50 Million ▲ +85.8%
2021 0.06x NT$1.26 Billion NT$74.15 Million ▼ -82.9%
2020 0.35x NT$526.35 Million NT$181.86 Million ▲ +498.3%
2019 0.06x NT$1.21 Billion NT$69.86 Million ▼ -16.3%
2018 0.07x NT$1.07 Billion NT$74.09 Million ▼ -29.0%
2017 0.10x NT$996.52 Million NT$96.79 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow